Graft Polymer (UK) PLC Proactive Investors Interview with CEO and Chair

RNS Number : 5071Q

Graft Polymer (UK) PLC

18 December 2024

 

RNS Reach - non-regulatory announcement

18 December 2024

Graft Polymer (UK) Plc
("Graft Polymer" or the "Company")

 

Proactive Investors interviews with CEO and Chairman

 

Graft Polymer, an innovative biotechnology company co-developing therapeutics for mental health disorders, announces interviews on Proactive Investors with Anthony Tennyson, CEO and Dennis Purcell, Chairman. The interview with Anthony Tennyson can we viewed now at https://www.proactiveinvestors.co.uk/LON:GPL/Graft-Polymer-UK-PLC and the interview with Dennis Purcell will be available from this Thursday, 19 December 2024.

 

 

Enquiries:

 

Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director. [e-mail]

 

Allenby Capital (Financial Adviser and Broker) [phone]

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

 

 

About Graft Polymer (UK) Plc

 

Graft Polymer (UK) Plc is an innovative biotechnology company focused on developing intellectual property relating to the treatment of mental health and substance use disorders, and the co-development of therapeutics for mental health disorders.  Our mission is to improve outcomes for individuals suffering from these conditions, with an initial focus on trauma-related mental health disorders, such as PTSD, which affected approximately 13 million adults in the U.S. in 2020, with the Company estimating a current affected population of 20 million across the US, UK and key EU markets.

 

For more information, please visit www.graftpolymer.co.uk.

 

About Reach announcements

This is an RNS Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain.  Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAGGBDDSDBDGSI